Early puberty and risk for type 2 diabetes in men.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
06 2020
Historique:
received: 12 12 2019
accepted: 10 02 2020
pubmed: 24 3 2020
medline: 30 9 2021
entrez: 24 3 2020
Statut: ppublish

Résumé

The association between pubertal timing and type 2 diabetes, independent of prepubertal BMI, is not fully understood. The aim of the present study was to evaluate the association between pubertal timing and risk of adult type 2 diabetes, independent of prepubertal BMI, in Swedish men. We included 30,697 men who had data for BMI at age 8 and 20 years and age at Peak Height Velocity (PHV), an objective assessment of pubertal timing, available from the BMI Epidemiology Study Gothenburg (BEST Gothenburg), Sweden. Information on type 2 diabetes (n = 1851) was retrieved from the Swedish National Patient Register. HRs and 95% CIs were estimated by Cox regression analysis. We observed violations of the assumption of proportional hazards for the association between age at PHV and the risk of type 2 diabetes and therefore split the follow-up period at the median age of type 2 diabetes diagnosis (57.2 years of age) to define early (≤57.2 years) and late (>57.2 years) type 2 diabetes diagnosis. Age at PHV was inversely associated with both early (HR 1.28 per year decrease in age at PHV, 95% CI 1.21, 1.36) and late (HR 1.13, 95% CI 1.06, 1.19) type 2 diabetes. After adjustment for childhood BMI, the associations between age at PHV and both early (HR 1.24, 95% CI 1.17, 1.31) and late (HR 1.11, 95% CI 1.05, 1.17) type 2 diabetes were similar. Moreover, early age at PHV predicted insulin treatment of type 2 diabetes (OR 1.25 per year decrease in age at PHV, 95% CI 1.17, 1.33). Assuming a higher risk among those with an age at PHV below the median, the population attributable factor indicates that 15% fewer of the diagnosed individuals would have developed type 2 diabetes had they not reached puberty early. These findings indicate that early puberty may be a novel independent risk factor for type 2 diabetes.

Identifiants

pubmed: 32201902
doi: 10.1007/s00125-020-05121-8
pii: 10.1007/s00125-020-05121-8
pmc: PMC7228987
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1141-1150

Subventions

Organisme : Hjärt-Lungfonden
ID : 20190624
Pays : International
Organisme : Vetenskapsrådet
ID : 2018-02597
Pays : International
Organisme : Lars Erik Lundbergs Stiftelse för Forskning och Utbildning
ID : 2017-0081
Pays : International
Organisme : Knut och Alice Wallenbergs Stiftelse
ID : KAW2015.0317
Pays : International
Organisme : NovoNordisk Foundation
ID : NNF180C0033898
Pays : International
Organisme : Grants from the Swedish state under the agreement between the Swedish government and county councils (ALF-agreement)
ID : ALFGBG-723791
Pays : International
Organisme : Torsten Söderbergs Stiftelse
ID : M65/15
Pays : International

Références

Obesity (Silver Spring). 2017 May;25(5):965-971
pubmed: 28345789
N Engl J Med. 2018 Apr 05;378(14):1302-1312
pubmed: 29617589
J Clin Endocrinol Metab. 2019 May 1;104(5):1823-1832
pubmed: 30517677
Sci Rep. 2015 Jun 18;5:11208
pubmed: 26084728
BMC Med Res Methodol. 2011 Jan 17;11:7
pubmed: 21241500
Diabetes Care. 2013 Nov;36(11):3526-34
pubmed: 24159179
J Epidemiol Community Health. 2006 Nov;60(11):993-7
pubmed: 17053289
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
BMJ. 2018 Feb 22;360:k757
pubmed: 29472187
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Obes Rev. 2017 Nov;18(11):1272-1288
pubmed: 28872224
Vital Health Stat 11. 2002 May;(246):1-190
pubmed: 12043359
Br J Cancer. 2010 Nov 23;103(11):1760-4
pubmed: 21045834
J Obes. 2011;2011:180729
pubmed: 21773002
N Engl J Med. 1982 Apr 29;306(17):1033-5
pubmed: 7062994
Pediatrics. 2008 Feb;121 Suppl 3:S208-17
pubmed: 18245513
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1017-1024
pubmed: 27815089
J Pediatr. 2015 Aug;167(2):344-52.e1
pubmed: 25962931
Am J Clin Nutr. 2018 Dec 1;108(6):1259-1263
pubmed: 30321255
J Pediatr Endocrinol Metab. 2009 Apr;22(4):291-9
pubmed: 19554802
JAMA Pediatr. 2019 Jul 22;:
pubmed: 31329245
Stat Med. 1987 Mar;6(2):185-92
pubmed: 3589247
Br J Cancer. 1999 Apr;79(11-12):1907-11
pubmed: 10206312
Int J Obes (Lond). 2013 Aug;37(8):1036-43
pubmed: 23164700
Diabetes Care. 2012 Apr;35(4):850-6
pubmed: 22338106
Diabetes. 2006 Nov;55(11):3047-52
pubmed: 17065341
Diabetologia. 2008 May;51(5):781-6
pubmed: 18320165
Endocr Rev. 2003 Oct;24(5):668-93
pubmed: 14570750
Diabet Med. 2012 May;29(5):600-3
pubmed: 21999522
Pediatrics. 2002 Oct;110(4):e43
pubmed: 12359816
Int J Obes (Lond). 2006 Jan;30(1):14-22
pubmed: 16344844
J Clin Endocrinol Metab. 2012 Aug;97(8):2844-52
pubmed: 22654120

Auteurs

Claes Ohlsson (C)

Centre for Bone and Arthritis Research, Institute of Medicine, the Sahlgrenska Academy at University of Gothenburg, Klinfarmlab, Vita Stråket 11, Sahlgrenska University Hospital, S-413 45, Gothenburg, Sweden.
Department of Drug Treatment, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.

Maria Bygdell (M)

Centre for Bone and Arthritis Research, Institute of Medicine, the Sahlgrenska Academy at University of Gothenburg, Klinfarmlab, Vita Stråket 11, Sahlgrenska University Hospital, S-413 45, Gothenburg, Sweden.

Maria Nethander (M)

Centre for Bone and Arthritis Research, Institute of Medicine, the Sahlgrenska Academy at University of Gothenburg, Klinfarmlab, Vita Stråket 11, Sahlgrenska University Hospital, S-413 45, Gothenburg, Sweden.
Bioinformatics Core Facility, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Jenny M Kindblom (JM)

Centre for Bone and Arthritis Research, Institute of Medicine, the Sahlgrenska Academy at University of Gothenburg, Klinfarmlab, Vita Stråket 11, Sahlgrenska University Hospital, S-413 45, Gothenburg, Sweden. Jenny.kindblom@gu.se.
Pediatric Clinical Research Center, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden. Jenny.kindblom@gu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH